fashion -WSS

fashion

author：leisure time 2025-09-27 12:21:40 - browse：96

Illustration of researchers working among oversized pill bottles, lab equipment, and medicine for story about the development of obesity medications – health and pharma coverage from STAT — Molly Ferguson for STAT

The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to develop their own obesity treatments, with most of them trying to emulate the same approach as the blockbuster products.

Nearly 70 obesity treatments are in development, and about two-thirds use a similar mechanism as Wegovy and Mounjaro, according to the STAT Obesity Drug Tracker, a new database compiled by STAT. There are also a minority of companies pursuing entirely different approaches, hoping that they will stand out among the field.

The tracker, which will be updated with significant developments each quarter, gives a sense of what new mechanisms could hit the market, how they would be delivered, and which companies are running the most trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Why are Kaiser Permanente staff considering a strike?

WSS

Lasker Awards 2023: Winners in biomedical research

Medical student insurance fails on mental health care coverage

Thermo Fisher plant for manufacturing gene therapies to expand

Biotech stock slump in 2023: awaiting the turnaround

How AI helped researchers track recovery from depression

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

explore

fashion

focus

Trump demands the U.S. pay no more for drugs than other countries … again

Thermo Fisher plant for manufacturing gene therapies to expand

What does generative AI mean for health care? We asked experts

New oral drug delivery patch is modeled after octopus tentacles

FDA approval of Sarepta Duchenne genetic therapy gives me hope

It's been 20 years since Dolly the sheep. Where's my clone?

The cancer drug shortage isn’t new — and neither are the solutions

It's been 20 years since Dolly the sheep. Where's my clone?

Cancer drug shortages should be causing more outrage

Drug for rare kidney disease narrowly misses mark in clinical trial

knowledge

Study points to new risk in gene therapy death of Terry Horgan

IVG is promising — but it won’t replace IVF quite yet

Experts study whether long Covid risk adds up with each reinfection

It's been 20 years since Dolly the sheep. Where's my clone?

What will Novo Nordisk's VC do with its influx of cash?

Medicare innovation center doesn’t save money, experts say

leisure time

explore

focus

focus